AGOC
Slides: INTEGRATE IIa: Randomised double-blind Phase III  study of regorafenib versus placebo in refractory  advanced Gastro-Oesophageal Cancer (AGOC).

Released: January 25, 2023

Expiration: January 24, 2024

Activity

Progress
1
Course Completed